Italiano et al. also reported a series of two patients with malignant metastatic uterine PEComas, one treated successfully with the mTOR inhibitor temsirolimus (now disease free following resection of her pulmonary metastasis) and the other showing a partial response followed by disease progression, with the temsirolimus being stopped at 22 weeks because of this [15]. This evidence concerns the gene MTOR and neoplasm with perivascular epithelioid cell differentiation.